Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Tribune Publishing Company is a publishing business based in the US. Tribune Publishing Company shares (TPCO) are listed on the NASDAQ and all prices are listed in US Dollars. Tribune Publishing Company employs 4,114 staff and has a trailing 12-month revenue of around USD$840.5 million.
|Latest market close||USD$12.6|
|52-week range||USD$4.91 - USD$13.15|
|50-day moving average||USD$12.2918|
|200-day moving average||USD$11.3272|
|Wall St. target price||USD$16.5|
|Dividend yield||USD$1 (8.2%)|
|Earnings per share (TTM)||USD$-0.097|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||N/A|
|1 month (2020-12-22)||2.44%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
Valuing Tribune Publishing Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tribune Publishing Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tribune Publishing Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$80.7 million.
The EBITDA is a measure of a Tribune Publishing Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$840.5 million|
|Operating margin TTM||5.25%|
|Gross profit TTM||USD$572.9 million|
|Return on assets TTM||4.3%|
|Return on equity TTM||-11.74%|
|Market capitalisation||USD$465.8 million|
TTM: trailing 12 months
There are currently 1.0 million Tribune Publishing Company shares held short by investors – that's known as Tribune Publishing Company's "short interest". This figure is 2.3% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting Tribune Publishing Company shares can be evaluated.
Tribune Publishing Company's "short interest ratio" (SIR) is the quantity of Tribune Publishing Company shares currently shorted divided by the average quantity of Tribune Publishing Company shares traded daily (recently around 78620.508866615). Tribune Publishing Company's SIR currently stands at 12.97. In other words for every 100,000 Tribune Publishing Company shares traded daily on the market, roughly 12970 shares are currently held short.
However Tribune Publishing Company's short interest can also be evaluated against the total number of Tribune Publishing Company shares, or, against the total number of tradable Tribune Publishing Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tribune Publishing Company's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Tribune Publishing Company shares in existence, roughly 30 shares are currently held short) or 0.0617% of the tradable shares (for every 100,000 tradable Tribune Publishing Company shares, roughly 62 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Tribune Publishing Company.
Find out more about how you can short Tribune Publishing Company stock.
We're not expecting Tribune Publishing Company to pay a dividend over the next 12 months.
Over the last 12 months, Tribune Publishing Company's shares have ranged in value from as little as $4.91 up to $13.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tribune Publishing Company's is 1.1643. This would suggest that Tribune Publishing Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Tribune Publishing Company, together with subsidiaries, publishes newspapers worldwide. The company operates in two segments, M and X. It publishes daily newspapers, weekly newspapers, and niche publications and direct mails; and operates local websites and mobile applications. The company also provides various digital marketing services, which include the development of mobile websites, search engine marketing and optimization, social media account management, and content marketing for its customers' web presence for small to medium size businesses. In addition, it operates Tribune Content Agency, a syndication and licensing business that provides daily news service and syndicated premium content to approximately 2,000 media and digital information publishers. Tribune Publishing Company operates in eight markets with Chicago Tribune, New York Daily News, The Baltimore Sun, Orlando Sentinel Sun Sentinel, Daily Press and The Virginian-Pilot, The Morning Call of Lehigh Valley, Pennsylvania, and the Hartford Courant titles; and BestReviews engages in business of testing, researching, and reviewing consumer products. The company was formerly known as tronc, Inc. and changed its name to Tribune Publishing Company in October 2018. Tribune Publishing Company was founded in 2013 and is headquartered in Chicago, Illinois.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.